Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
- 1 September 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Clinical Psychopharmacology
- Vol. 25 (5), 247-256
- https://doi.org/10.1097/yic.0b013e32833948fa
Abstract
This 13-week, double-blind study evaluated the efficacy and safety of the atypical antipsychotic paliperidone palmitate (recently approved in the United States) versus placebo administered as monthly gluteal injections (after two initial doses given 1 week apart) in acutely symptomatic patients with schizophrenia. Patients (N=388) were randomly assigned (1 : 1 : 1 : 1) to paliperidone palmitate 50, 100, or 150 mg eq. or placebo. As the 150 mg eq. dose was administered to fewer patients (n=30) than planned, meaningful and definitive conclusions cannot be drawn from the results of this group. The change from baseline in Positive and Negative Syndrome Scale total score at endpoint showed improvement in both paliperidone palmitate 50 and 100 mg eq. groups but was significant only in the 100 mg eq. group (P=0.019). The paliperidone palmitate 50 (P=0.004) and 100 mg eq. (Por=2% of patients in any group) more frequent with paliperidone palmitate 50 or 100 mg eq. than placebo (>or=5% difference) were headache, vomiting, extremity pain, and injection site pain. Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable.Keywords
This publication has 18 references indexed in Scilit:
- Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled studySchizophrenia Research, 2010
- Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
- Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the communityQuality of Life Research, 2008
- Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophreniaSchizophrenia Research, 2008
- The Burden of Schizophrenia on CaregiversPharmacoEconomics, 2008
- Intramuscular injections into the buttocks: Are they truly intramuscular?European Journal of Radiology, 2006
- Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical AntipsychoticAmerican Journal of Psychiatry, 2003
- Intramuscular Preparations of AntipsychoticsDrugs, 2003
- Guidelines for depot antipsychotic treatment in schizophreniaEuropean Neuropsychopharmacology, 1998
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989